This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech 2005: New Drugs Hold the Key

2004's Biotech Movers

Returning to the theme of winners and losers in 2004, these companies stood out for their performance, both positive and negative.

Biogen Idec, at Tuesday's close of $67.86, was up almost 84% in 2004, largely on the back of its recently approved multiple sclerosis drug Tysabri. Shares of Biogen Idec first soared in February when the company surprised almost everyone by announcing that it would seek earlier-than-expected FDA approval for Tysabri. The drug, a blockbuster in the making with potential sales well in excess of $1 billion, was approved in late November.

Amgen, the biotech sector's largest company, was a laggard for most of the year, stung by investor concerns over changes to Medicare drug reimbursement rules and slowing sales growth. But negative returns in 2004 were erased by a late fall rally. At Tuesday's close of $64.60, the stock is up 3.6% for the year.

Gilead Sciences (GILD - Get Report), buoyed by strong sales growth in its core AIDS/HIV drug franchise and the approval of a new combination HIV medicine Truvada, is up 21% for the year.

ImClone Systems (IMCL) started the year strong with the approval of its colon cancer drug Erbitux, but the stock swooned midyear and is now up just 14.5%.

OSI Pharmaceuticals had a seesaw year, with shares shooting up, down and then up again on the prospects for its lung cancer drug Tarceva.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ITMN $73.89 -0.03%
IMCL $0.35 0.00%
BIIB $252.20 0.00%
CORT $3.49 0.00%
CYTK $7.00 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs